• Poly (I:C): Synthetic Double-Stranded RNA Analog in Immunity

  2026-06-25

  Poly (I:C) uniquely models innate immune activation and dendritic cell maturation, offering robust interferon induction for in vitro and in vivo workflows. Recent evidence on dsRNA sensing in cardiomyocytes highlights new assay design opportunities for disease modeling and immune regulation.

• Bile Acid Metabolism Subtypes Reveal Prognostic CRC Immune M

  2026-06-25

  Feng et al. (2026) present an integrative transcriptomic approach that subtypes colorectal cancer (CRC) by bile acid metabolism, identifying CLCA1, UGT2A3, and ZG16 as immune-related markers linked to prognosis. Their findings provide new insights into the tumor immune microenvironment and open avenues for biomarker-driven patient stratification and therapeutic research.

• Nystatin (Fungicidin): Mechanistic Insights and Advanced Ant

  2026-06-24

  Explore the multifaceted antifungal properties of Nystatin (Fungicidin), including its unique mechanism, quantitative efficacy against Candida species, and advanced research applications. This article delivers original scientific analysis and practical assay guidance, extending beyond existing workflows.

• HyperScript RT SuperMix for qPCR: Advancing Difficult RNA An

  2026-06-23

  Discover how HyperScript RT SuperMix for qPCR overcomes the toughest challenges in reverse transcription, enabling precise cDNA synthesis even from complex or low-concentration RNA. This article reveals unique protocol strategies and integrates key insights from angiogenesis research to elevate gene expression analysis.

• Carcinogen-Induced seRNA Drives NPC Metastasis via NPM1/c-My

  2026-06-23

  This study uncovers how N,N’-Dinitrosopiperazine (DNP) exposure induces a unique super-enhancer RNA (seRNA-NPCm), which promotes nasopharyngeal carcinoma (NPC) metastasis by activating the NPM1/c-Myc/NDRG1 axis. These findings reveal new molecular mechanisms underlying NPC progression and highlight potential avenues for targeted research and prognostic biomarker discovery.

• 2,5-di-tert-butylbenzene-1,4-diol (BHQ): Revolutionizing SER

  2026-06-22

  2,5-di-tert-butylbenzene-1,4-diol (BHQ) from APExBIO delivers targeted SERCA inhibition, enabling unprecedented control over calcium homeostasis disruption and hematopoietic stem cell mobilization. Integrating robust mechanistic insight with workflow-ready protocols, BHQ empowers stem cell and vascular researchers to achieve reproducible, high-yield outcomes.

• FGF4-FGFR1 Axis Preserves Podocyte Survival in Diabetic Kidn

  2026-06-22

  This study uncovers the essential role of podocyte-secreted FGF4 and FGFR1 signaling in maintaining glomerular function and mitigating diabetic kidney disease (DKD) progression in male mice. By dissecting the FGFR1-AMPK-FOXO1 pathway, the authors provide new mechanistic insight and a potential therapeutic target for DKD intervention.

• Berberine Hydrochloride: AMPK, Gut-Bone Axis, and Metabolic

  2026-06-21

  Explore the multifaceted research uses of berberine hydrochloride in modulating AMPK activity, gut-bone signaling, and metabolic pathways. This article offers unique, protocol-ready insights that build on recent breakthroughs while guiding advanced assay design.

• CENPI Drives Breast Cancer Progression via Wnt/β-Catenin Axi

  2026-06-20

  Wu et al. (2025) identify centromere protein I (CENPI) as a key oncogenic driver in breast cancer, demonstrating its direct role in tumorigenesis and disease progression through modulation of the Wnt/β-catenin pathway. Their integrative approach combines transcriptomic analysis, functional assays, and in vivo modeling, providing a robust foundation for targeting CENPI in future therapeutic and biomarker strategies.

• Applied Workflows with Nystatin (Fungicidin) in Antifungal R

  2026-06-19

  Nystatin (Fungicidin) from APExBIO stands out for its robust utility in both basic and translational antifungal research—enabling precise inhibition of Candida and Aspergillus species, including drug-resistant isolates. This guide details advanced workflows, practical troubleshooting, and protocol innovations, all backed by key reference findings and optimized for experimental reproducibility.

• SP2509: Advancing Epigenetic Therapy in AML Translational Re

  2026-06-19

  Explore how SP2509, a potent lysine-specific demethylase 1 antagonist, is reshaping acute myeloid leukemia (AML) research. This article blends mechanistic insight with strategic guidance, addressing experimental validation, translational relevance, and the competitive landscape—while highlighting how SP2509 from APExBIO enables advanced cancer epigenetics workflows, and what this means for the future of precision oncology.

• 740 Y-P: Optimizing PI 3-Kinase Activator Workflows in Cell

  2026-06-18

  740 Y-P enables precise, reproducible activation of the PI3K/AKT pathway for advanced vesicular trafficking, apoptosis, and neuronal survival studies. Its robust solubility and validated workflow enhancements make it a go-to tool for researchers seeking pathway-specific insights and troubleshooting solutions.

• Angiotensin II (SKU A1042): Scenario-Driven Lab Solutions

  2026-06-18

  This article delivers a scenario-based, evidence-grounded exploration of Angiotensin II (SKU A1042) for cell viability, proliferation, and vascular modeling workflows. Focusing on real laboratory challenges, it demonstrates how APExBIO’s Angiotensin II supports reliable, reproducible assays with data-backed protocol guidance and vendor selection insights.

• HPF: Redefining Selective hROS Detection in Tumor Microenvir

  2026-06-17

  Discover how HPF (hydroxyphenyl fluorescein) advances highly reactive oxygen species detection in complex tumor microenvironments. This article uniquely explores HPF's role in multimodal cancer therapy and practical assay design, offering insights far beyond standard protocol guides.

• Optimizing Cell Assays with Dovitinib (TKI-258, CHIR-258): P

  2026-06-17

  This article delivers scenario-driven guidance for deploying Dovitinib (TKI-258, CHIR-258) (SKU A2168) in cell viability and apoptosis assays. Covering reproducibility, protocol optimization, and vendor reliability, it demonstrates how data-backed practices and robust product attributes from APExBIO ensure experimental success in RTK-driven cancer research.

485 records 9/33 page Previous Next First page 上5页 678910 下5页 Last page